NASDAQ:RKDA Arcadia Biosciences (RKDA) Stock Price, News & Analysis $0.26 -0.01 (-3.40%) As of 10/9/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsSEC Filings About Arcadia Biosciences Stock (NASDAQ:RKDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arcadia Biosciences alerts:Sign Up Key Stats Today's Range$0.23▼$0.2950-Day Range$0.26▼$0.7252-Week Range$0.22▼$5.72Volume390,238 shsAverage Volume2.75 million shsMarket Capitalization$636.96 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Arcadia Biosciences, Inc. is an agricultural biotechnology company focused on developing and commercializing plant-based products and crop technologies designed to address health, nutrition and sustainability needs. The company has worked to improve the nutritional profile and agricultural performance of crops through biotechnology and plant-breeding programs. Arcadia’s product portfolio has included GoodWheat, a line of wheat varieties and wheat-based foods developed to contain reduced levels of gluten and other targeted nutritional characteristics. The company has also pursued hemp-related products and other consumer health and wellness offerings, while historically developing crop traits intended to improve characteristics such as nitrogen-use efficiency, salinity tolerance and yield. Founded in 2002, Arcadia Biosciences has been based in Davis, California, and has served agricultural, food and consumer markets through research, product development, licensing and commercialization activities. Its business focus and product portfolio have evolved over time as the company has emphasized commercial opportunities in plant-based nutrition and wellness.AI Generated. May Contain Errors. Read More Arcadia Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreRKDA MarketRank™: Arcadia Biosciences scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingArcadia Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageArcadia Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Arcadia Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Arcadia Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.86% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently increased by 824.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.37 News SentimentArcadia Biosciences has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arcadia Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for RKDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Arcadia Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders4.50% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by Institutions17.73% of the stock of Arcadia Biosciences is held by institutions.Read more about Arcadia Biosciences' insider trading history. Receive RKDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RKDA Stock News HeadlinesArcadia Biosciences, Inc. (NASDAQ:RKDA) Sees Large Increase in Short InterestOctober 10 at 2:23 AM | americanbankingnews.comArcadia Biosciences (NASDAQ:RKDA) Shares Cross Below 50-Day Moving Average - Here's What HappenedOctober 7 at 3:21 AM | americanbankingnews.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 10 at 1:00 AM | Porter & Company (Ad)Financial Contrast: Arcadia Biosciences (NASDAQ:RKDA) & Constellation Brands (NYSE:STZ)October 4, 2026 | americanbankingnews.comArcadia Biosciences, Inc. (NASDAQ:RKDA) Stock Short Interest Declines 48.8%September 29, 2026 | americanbankingnews.comArcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business HighlightsAugust 13, 2026 | globenewswire.comRKDA Share News TodayJuly 6, 2026 | uk.investing.comArcadia Biosciences, Inc.: Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesJune 13, 2026 | finanznachrichten.deSee More Headlines RKDA Stock Analysis - Frequently Asked Questions How have RKDA shares performed this year? Arcadia Biosciences' stock was trading at $1.98 on January 1st, 2026. Since then, RKDA shares have decreased by 86.7% and is now trading at $0.2643. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences, Inc. (NASDAQ:RKDA) released its quarterly earnings results on Thursday, August, 13th. The basic materials company reported ($2.09) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $1.53. The basic materials company had revenue of $1.44 million for the quarter, compared to the consensus estimate of $1.90 million. Arcadia Biosciences had a negative net margin of 234.53% and a negative trailing twelve-month return on equity of 183.50%. When did Arcadia Biosciences' stock split? Arcadia Biosciences's stock reverse split before market open on Wednesday, January 24th 2018.The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Arcadia Biosciences IPO? Arcadia Biosciences (RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO. How do I buy shares of Arcadia Biosciences? Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcadia Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), GE Aerospace (GE), Arista Networks (ANET), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/13/2026Today10/10/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RKDA's financial health is in the Red zone, according to TradeSmith. RKDA has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Staples Industry Beverages Sub-IndustrySoft Drinks & Non-alcoholic Beverages Current SymbolNASDAQ:RKDA CIK1469443 Webwww.arcadiabio.com Phone(214) 974-8921Fax530-756-7027Employees8Year Founded2002Profitability EPS (Trailing Twelve Months)($4.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.34 million Net Margins-234.53% Pretax Margin-234.37% Return on Equity-183.50% Return on Assets-91.25% Debt Debt-to-Equity RatioN/A Current Ratio3.49 Quick Ratio2.92 Sales & Book Value Annual Sales$4.86 million Price / Sales0.13 Cash Flow$1.26 per share Price / Cash Flow0.21 Book Value$2.39 per share Price / Book0.11Miscellaneous Outstanding Shares2,410,000Free Float2,301,000Market Cap$636.96 thousand OptionableNot Optionable Beta0.56 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:RKDA) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredTech expert smashes iPhone with golf clubTwenty years ago, Josh Baylin told Congress the iPhone was coming, three years before it launched. A $1,500 be...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcadia Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcadia Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
